DA-JC4
Modify Date: 2025-08-25 11:08:58
DA-JC4 structure
|
Common Name | DA-JC4 | ||
|---|---|---|---|---|
| CAS Number | 2315504-40-4 | Molecular Weight | 4875.49 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C225H346N56O65 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of DA-JC4DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways[1][2][3]. |
| Name | DA-JC4 |
|---|
| Description | DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
GLP-1/GIP[1] |
| In Vitro | DA-JC4 (1~100 nM; hippocampal cells) inhibits rotenone-induced hippocampal neuron death and significantly suppresses Cyt C, Bax and Caspase activation[3]. |
| In Vivo | DA-JC4 (10 nmol/kg; i.p.; once-daily for 14 days) significantly prevents spatial learning deficits in a Y- maze test and Morris water maze tests, and decreases phosphorylated tau levels in the rat cerebral cortex and hippocampus[1]. DA-JC4 (25 nmol/kg; i.p.; 6 days) shows high levels expression of tyrosine Hydroxylase in the s. nigra and increases expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF)[2]. DA-JC4 (50 nmol/kg; i.p.; once-daily for 7 days) improves Parkinson's disease symptom potentially and enhances neurotransmission[3]. Animal Model: Male Sprague-Dawley rats (210–230 g) Dosage: 10 nmol/kg Administration: I.p. Result: Significantly prevented spatial learning deficits in a Y- maze test and Morris water maze tests, and decreased phosphorylated tau levels in the rat cerebral cortex and hippocampus. Animal Model: Adult male C57BL/6 mice (8 week-old) Dosage: 25 nmol/kg/day Administration: I.p. Result: Showed high levels expression of tyrosine Hydroxylase in the s. nigra and increased expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF). Animal Model: Adult male Sprague-Dawley (SD) rats (230-280 g) Dosage: 50 nmol/kg Administration: I.p. Result: Improved Parkinson's disease symptom potentially and enhanced neurotransmission. |
| References |
| Molecular Formula | C225H346N56O65 |
|---|---|
| Molecular Weight | 4875.49 |